Anzeige
Mehr »
Login
Samstag, 19.06.2021 Börsentäglich über 12.000 News von 662 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 885823 ISIN: US3755581036 Ticker-Symbol: GIS 
Tradegate
18.06.21
21:53 Uhr
56,09 Euro
-0,39
-0,69 %
1-Jahres-Chart
GILEAD SCIENCES INC Chart 1 Jahr
5-Tage-Chart
GILEAD SCIENCES INC 5-Tage-Chart
RealtimeGeldBriefZeit
55,9756,3112:54
56,0856,1918.06.

Aktuelle News zur GILEAD SCIENCES Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrGilead's Kite makes off-the-shelf play with Shoreline Biosciences CAR-NK deal worth as much as $2.3B13
FrGilead (GILD) Inks Deal to Develop Allogeneic Cell Therapies12
GILEAD SCIENCES Aktie jetzt für 0€ handeln
DoFate Therapeutics is expected to dominate in cell therapy despite Gilead's entry15
DoGilead's Kite Pharma Collaborates With Shoreline Biosciences For Cell Therapies For Cancer Settings15
DiJounce Therapeutics Stock Is Trading After $25M In Milestone Payment From Gilead18
DiFDA approves oral pellet version of Gilead's Epclusa for use in young hepatitis C patients13
DiJounce shares rise on $25M milestone payment from Gilead12
MoGilead Sciences, Inc. (GILD) Fell Out Of Favor With Hedge Funds36
MoGilead company, Kite's Yescarta shows survival improvement in follicular lymphoma32
11.06.Gilead (GILD) Gets FDA Nod for Label Expansion of Epclusa20
11.06.FDA approves new formulation Gilead's Epclusa for children ages 3 and older with HCV28
11.06.Gilead: FDA Oks Epclusa, Expanding Pediatric Indication To Treat Children With Chronic Hepatitis C583FOSTER CITY (dpa-AFX) - Gilead Sciences Inc. (GILD) said that the U.S. Food and Drug Administration has approved new formulation of Epclusa, expanding pediatric indication to treat children...
► Artikel lesen
10.06.'Halftime Report' Traders Share Their Thoughts On Gilead, IBM And More38
10.06.Gilead Sciences, Inc. (GILD) Management Presents at Goldman Sachs 42nd Annual Global Healthcare Conference (Transcript)44
06.06.Gilead Sciences: An Underestimated Gem With Plenty Of Optionality79
06.06.Gilead Sciences: Rebuilding Under No Real Pressure - Buy For Near-Term Profits, Upside50
04.06.Gilead's Trodelvy New Subgroup Data Shows Benefit in Second-Line Breast Cancer Patients22
04.06.ASCO: Gilead's Kite soars over Novartis' CAR-T turf with Tecartus win in type of leukemia52
04.06.Elizabeth Warren wants Gilead CEO Daniel O'Day in the hot seat to talk drug pricing and competitiveness25
04.06.Gilead highlights potential of Trodelvy in breast cancer as second line therapy13
Seite:  Weiter >>
486 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
30,13,65